Using nanotechnology to target pancreatic cancer and its environment
Targeting tumor and its microenvironment using nanotherapeutics for pancreatic cancer
['FUNDING_R01'] · UNIVERSITY OF MISSOURI-COLUMBIA · NIH-10615062
This study is testing a new way to treat pancreatic cancer using a tiny device that delivers a special treatment directly to the tumor and its surroundings, which could make the therapy work better and have fewer side effects for patients.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF MISSOURI-COLUMBIA (nih funded) |
| Locations | 1 site (COLUMBIA, UNITED STATES) |
| Trial ID | NIH-10615062 on ClinicalTrials.gov |
What this research studies
This research focuses on improving treatment for pancreatic cancer by developing a dual delivery nanoscale device that can simultaneously target the tumor and its surrounding environment. The approach aims to overcome challenges such as drug resistance and side effects associated with traditional therapies. By delivering a specific microRNA (miR-345) alongside a chemotherapy drug, the research seeks to enhance treatment efficacy and potentially improve patient outcomes. Patients may benefit from a more effective therapy that addresses the complexities of pancreatic cancer.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with pancreatic cancer, particularly those who have not responded well to existing therapies.
Not a fit: Patients with early-stage pancreatic cancer who have not yet undergone treatment may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for pancreatic cancer, potentially improving survival rates and quality of life for patients.
How similar studies have performed: Previous research has shown promise in using nanotherapeutics for cancer treatment, indicating that this approach could be a viable option for pancreatic cancer as well.
Where this research is happening
COLUMBIA, UNITED STATES
- UNIVERSITY OF MISSOURI-COLUMBIA — COLUMBIA, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: RACHAGANI, SATYANARAYANA — UNIVERSITY OF MISSOURI-COLUMBIA
- Study coordinator: RACHAGANI, SATYANARAYANA
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.